Searchable abstracts of presentations at key conferences in endocrinology

ea0033cme4 | CME TRAINING DAY | BSPED2013

Normal and abnormal variations of growth and puberty: how can the new RCPCH specialist childhood and puberty close monitoring charts help us?

Butler G

Growth through the pubertal progress is notoriously difficult to track and interpreting abnormal patterns is tricky. Current growth charts are unhelpful. I will present new analyses of understanding of growth patterns and the tempo of pubertal changes and how they all link together. The RCPCH has launched a specialist growth chart in June to help identify and diagnose abnormal growth patterns during puberty. These include growth centiles for extremes of stature and weight, and...

ea0007p131 | Growth and development | BES2004

Do prolonged courses of testosterone affect final height in extreme maturational delay?

Lee R , Butler G

Aim: Differentiating idiopathic hypogonadotrophic hypogonadism from extreme maturational delay can be difficult, so most boys receive testosterone (T) replacement until the diagnosis becomes clear. Standard 3 month T therapy for maturational delay does not diminish adult stature, so we set out to determine whether T treatment of greater than 6 months duration would have an adverse effect on final height (FH) in boys with the eventual diagnosis of extreme maturational delay.</p...

ea0024p22 | (1) | BSPED2010

GHT does not improve QOL in all conditions

Eiser C , Wright N P , Butler G , Otero S C

Growth hormone treatment (GHT) is used to improve height, and potentially quality of life (QOL), in children with abnormal growth patterns. Previous QOL research suggests children with acquired growth hormone deficiency (AGHD) benefit more from GHT than those treated for other conditions.The aim was to determine child and parent reported QOL change over 1 year depending on GHT and diagnosis.One hundred and twenty-two children (mean...

ea0017p11 | (1) | BSPED2008

GH treatment and quality of life: the practicalities of running a multi-centre research study

Wales G , Bailey L , Eiser C , Wright N , Butler G

Background: The National Institute for Clinical Excellence (NICE, 2002) suggests that measurement of quality of life (QOL) is necessary to assess the efficacy of GH treatment (GHT). A pilot study (Sheppard 2006) showed a greater improvement in QOL over the first 6 months of GHT for patients with acquired GH deficiency (AGHD) compared with idiopathic GH deficiency (IGHD).Method: In view of this, a longitudinal research study was set up to measure changes ...

ea0003p164 | Growth and Development | BES2002

Monitoring insulin-like growth factor-I and IGF binding protein-3 in children and adolescents on GH treatment using filter paper blood spots

Das U , Price D , Khosravi J , Wales J , Butler G , Kibirige M , Diamandi A , Jones J , Hall C , Clayton P

In childhood an appropriate response to GH treatment is achieved by titration of growth response against dose administered, with careful observation for side-effects. In order to evaluate the potential use of IGF monitoring in children treated with GH, a cross-sectional study has been carried in 215 children and adolescents (134 with GH deficiency, 54 with Turner syndrome and 29 with non-GHD growth disorders) treated with GH for 0.2 to 13.7 years.IGF-I ...